ESR1 and metastatic neoplasm: Recently, with the advancement of sequencing techniques, recurrent mutations on ESR1 have been found to occur more frequently than expected in patients with ERα+ metastatic disease and contribute to acquired endocrine therapy resistance [9,10,11].